AURORA CANNABIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.005 EUR | +6.70% |
|
+11.46% | +57.31% |
| 16/05 | US Government Reclassifies Marijuana to Less-Restrictive Category | MT |
| 16/05 | Justice Department Set to Post Cannabis Reclassification Plans | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +57.31% | 414M | - | ||
| +42.64% | 6.28B | B- | ||
| -15.52% | 4.51B | C+ | ||
| +8.35% | 3.35B | C | ||
| -11.10% | 3.13B | B- | ||
| -4.12% | 2.47B | - | D+ | |
| +46.46% | 1.96B | - | ||
| -7.97% | 1.68B | - | - | |
| -1.07% | 1.63B | - | - | |
| -11.56% | 1.56B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ACB Stock
- 21P Stock
- Ratings Aurora Cannabis Inc.
